The Apolipoprotein C-I Content of Very-Low-Density Lipoproteins Is Associated with Fasting Triglycerides, Postprandial Lipemia, and Carotid Atherosclerosis

Table 1

Characteristics of study participants. Characteristics of subjects included in the study across tertiles of apoC-I molecules per VLDL particles (𝑛=81) under fasting conditions. Values are means ± 1 SD or percentage with number in brackets.

Variables	ApoC-I per VLDL			𝑃 for trend
	T1	T2	T3
Apo-CI per VLDL	3.5±1.1	6.2±0.9	12.8±3.1
Men (%)	56 (15)	56 (15)	56 (15)	1.00
Age (yrs)	68.1±5.5	69.3±6.7	70.4±6.6	0.19
Smoking (%)	19 (5)	22 (6)	22 (6)	0.68
Body mass index (kg/m^2)	26.8±3.9	26.1±3.8	26.7±3.9	0.93
Systolic blood pressure (mmHg)	127±17	130±17	132±20	0.30
Diastolic blood pressure (mmHg)	74±9	75±11	𝟕𝟑±𝟗	0.91
Total cholesterol (mmol/L)	6.27±1.22	5.68±1.63	6.26±0.98	0.98
HDL cholesterol (mmol/L)	1.87±0.53	1.76±0.44	1.67±0.46	0.13
LDL cholesterol (mmol/L)	3.89±0.91	4.02±1.11	3.97±0.85	0.76
Triglycerides (mmol/L)	0.90±0.36	1.25±0.67	1.35±0.77	0.01
Apolipoprotein A1 (g/L)	1.45±0.27	1.42±0.23	1.40±0.22	0.47
Apolipoprotein B (g/L)	1.06±0.20	1.07±0.23	1.11±0.18	0.44
Apolipoprotein C-I (mg/L)	206.7±59.0	205.5±65.9	215.7±76.1	0.66
Apolipoprotein C-II (mg/L)	34.4±10.5	40.1±15.3	44.8±19.1	0.015
Apolipoprotein C-III (mg/L)	107.2±40.6	109.2±39.7	130.8±45.4	0.12
Apolipoprotein E (mg/L)	42.1±12.5	40.4±15.0	46.1±17.4	0.34
Hypertension (%)	33 (9)	30 (8)	56 (15)	0.16
Diabetes (%)	4 (1)	19 (5)	7 (2)	0.65
Coronary artery disease (%)	19 (5)	4 (1)	30 (8)	0.29
Cerebrovascular events (%)	11 (3)	0 (0)	7 (2)	0.58
Antihypertensive drugs (%)	15 (4)	4 (1)	22 (6)	0.37
Platelet inhibitors (%)	15 (4)	11 (3)	19 (5)	0.62
Omega-3 FA supplementation (%)	52 (14)	44 (12)	56 (15)	0.79
Carotid plaques (%)	30 (8)	63 (17)	63 (17)	0.016
Plaque area (mm^2)	4.0±2.4	4.4±2.7	8.8±4.3	0.048